Literature DB >> 11373830

Evaluation of patients with decreased vision or blindness.

C L Martin1.   

Abstract

A good ocular examination and careful evaluation of the pupillary light reflexes will localize most lesion(s) producing a complaint of blindness. Lesions of the clear media severe enough to produce blindness will prohibit fundus examination. Retinal, optic nerve, and complete chiasmal lesions will produce dilated, slowly reactive pupils. Retinal blindness is usually associated with dramatic ophthalmoscopic lesions of diffuse altered reflectivity and vascular attenuation, the major exceptions being the sudden acquired retinal degeneration syndrome and some patients with glaucoma. Optic nerve lesions may involve the optic disc where they may be recognized by either pallor or hyperemia and cupping or elevation. Confirmation of optic nerve blindness in practice usually is by ruling out retinal blindness, but a more definitive methodology is to have a normal electroretinogram, slow or absent direct pupillary light reflexes (PLR), and abnormal visual evoked potentials. Central blindness is diagnosed by normal eyes, normal PLR, and often central nervous system (CNS) signs indicative of a diffuse or multifocal CNS disease.

Entities:  

Mesh:

Year:  2001        PMID: 11373830     DOI: 10.1053/svms.2001.22808

Source DB:  PubMed          Journal:  Clin Tech Small Anim Pract        ISSN: 1096-2867


  2 in total

1.  Animal Welfare Considerations and Ethical Dilemmas Inherent in the Euthanasia of Blind Canine Patients.

Authors:  Vito Biondi; Michela Pugliese; Eva Voslarova; Alessandra Landi; Annamaria Passantino
Journal:  Animals (Basel)       Date:  2022-04-02       Impact factor: 2.752

2.  Efficacy of the use of a colorimetric pupil light reflex device in the diagnosis of fundus disease or optic pathway disease in dogs.

Authors:  Kunihiko Terakado; Takuya Yogo; Yoshinori Nezu; Yasuji Harada; Yasushi Hara; Masahiro Tagawa
Journal:  J Vet Med Sci       Date:  2013-06-18       Impact factor: 1.267

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.